{"schema_version":1,"research_id":"eoa_inverse_innovation_exp06_external_evaluation_20260803","source_assessment_id":"catalytic_pathway_enablement__nanotechnology:P4:v0","cell_id":"catalytic_pathway_enablement__nanotechnology","search_queries":["site:cancer.gov nanotechnology characterization laboratory assay cascade collaboration characterization nanomaterials","MIRIBEL minimum information reporting bio nano experimental literature Nature Nanotechnology 2018","ISA-TAB-Nano standard nanomaterial data sharing official","nano bio interface sample handoff characterization service standard assay facility reproducibility","nanomedicine translation barriers reproducibility characterization assay standardization survey bio nano interface sample preparation","FDA nanomaterial drug products guidance characterization manufacturing controls 2022 official","European Commission JRC nanomaterials repository sample preparation characterization biological testing harmonisation","NCI NCL protocols sample submission requirements nanoparticle characterization official","site:bls.gov/ooh life physical social science occupations median pay 2025 biochemists biophysicists","site:bls.gov/oes 2025 medical scientists wage laboratory managers natural sciences managers","NCL sample submission application process required information nanoparticle official NCI","nanotechnology characterization laboratory protocols sample preparation endotoxin contamination assay interference official","site:pubmed.ncbi.nlm.nih.gov ISA-TAB-Nano specification sharing nanomaterial research data","site:iso.org/standard/68833 ISO 20579-4 2018","site:dctd.cancer.gov/research/research-areas/nanotech/ncl Assay Cascade 2025","site:cancer.gov nano collaborators Assay Cascade testimonial invaluable","doi 10.1186/1472-6750-13-2 BMC Biotechnology ISA-TAB-Nano","doi 10.1038/s41565-018-0246-4 MIRIBEL full text","site:joint-research-centre.ec.europa.eu/laboratories-z/nanobiotechnology-laboratory external researchers access","site:dctd.cancer.gov/research/research-areas/nanotech/ncl/about collaborators testimonials"],"sources":[{"source_id":"S1","title":"About the Nanotechnology Characterization Lab (NCL)","publisher":"U.S. National Cancer Institute","url":"https://dctd.cancer.gov/research/research-areas/nanotech/ncl/about","source_class":"OFFICIAL_ORGANIZATION_DATA","publication_date":"Not stated; page current at access","accessed_at":"2026-08-03","claims_supported":["NCI, FDA, and NIST established NCL as a public-private partnership to expedite nanotechnology translation.","NCL operates a multidisciplinary characterization service, has tested more than 500 nanomaterials, and offers Assay Cascade, cCRADA, and technical-service pathways.","An identifiable government authorizer and funder already operates a closely analogous standing nano-to-biology characterization service."]},{"source_id":"S2","title":"Minimum information reporting in bio–nano experimental literature","publisher":"Nature Nanotechnology","url":"https://www.nature.com/articles/s41565-018-0246-4","source_class":"PRIMARY_RESEARCH","publication_date":"2018-09-06","accessed_at":"2026-08-03","claims_supported":["Variability in characterization and experimental-detail reporting is described as a significant barrier in multidisciplinary bio-nano research.","MIRIBEL specifies minimum information across material characterization, biological characterization, and experimental protocols.","A reporting checklist is close prior art for the proposal's semantic intake contract but is not itself a standing handoff service."]},{"source_id":"S3","title":"ISA-TAB-Nano: a specification for sharing nanomaterial research data in spreadsheet-based format","publisher":"BMC Biotechnology / PubMed record","url":"https://pubmed.ncbi.nlm.nih.gov/23311978/","source_class":"PRIMARY_RESEARCH","publication_date":"2013-01-14","accessed_at":"2026-08-03","claims_supported":["The authors reported that nanomaterial data were often incomplete, poorly integrated, and unsuitable for interpretation and reuse.","ISA-TAB-Nano represents material descriptions, assay metadata, protocols, and endpoints using linked spreadsheet formats and ontology terms.","A structured sample passport and semantic contract substantially overlap established nanomaterial-data specifications."]},{"source_id":"S4","title":"Sample Preparation Protocols","publisher":"U.S. National Institute of Standards and Technology","url":"https://www.nist.gov/mml/sample-preparation-protocols","source_class":"OFFICIAL_GUIDANCE","publication_date":"Updated 2025-04-02","accessed_at":"2026-08-03","claims_supported":["NIST states that nanomaterial sample preparation is challenging because materials can agglomerate or transform in media and different measurements require different physical forms.","NIST publishes reporting and preparation protocols for nanoparticle dispersions used in biological and environmental testing.","Prevalidated preparation and reporting protocols are established practice, while reproducibility still requires measurement of material properties."]},{"source_id":"S5","title":"Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry","publisher":"U.S. Food and Drug Administration","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry","source_class":"GOVERNMENT_OR_REGULATOR","publication_date":"2022-04","accessed_at":"2026-08-03","claims_supported":["FDA states that nanomaterial-containing products can have distinctive attributes warranting particular examination.","For regulated drug development, an internal handoff service cannot replace applicable characterization, controls, testing, qualification, quality, safety, or regulatory obligations.","The proposed nonclinical pilot is feasible only if receiving authorities retain substantive acceptance authority and the service makes no safety certification."]},{"source_id":"S6","title":"Endotoxin & Depyrogenation Guide, Version 4","publisher":"U.S. National Cancer Institute via NCBI Bookshelf","url":"https://www.ncbi.nlm.nih.gov/books/NBK613264/","source_class":"OFFICIAL_GUIDANCE","publication_date":"2025-01","accessed_at":"2026-08-03","claims_supported":["NCL reports that nearly one-third of submitted formulations exceed recommended endotoxin limits, demonstrating a material and observable handoff-readiness problem.","Detailed synthesis and handling histories can help identify contamination sources.","Methods are not universal across nanomaterials; empirical confirmation and post-treatment integrity characterization remain necessary, limiting safe template scope."]},{"source_id":"S7","title":"Biochemists and Biophysicists: Occupational Outlook Handbook","publisher":"U.S. Bureau of Labor Statistics","url":"https://www.bls.gov/ooh/life-physical-and-social-science/biochemists-and-biophysicists.htm","source_class":"OFFICIAL_ORGANIZATION_DATA","publication_date":"2025 edition using May 2024 wage data","accessed_at":"2026-08-03","claims_supported":["The May 2024 median annual wage was $103,650, with a $126,100 median in scientific research and development services.","Interdisciplinary scientific judgment, documentation, quality monitoring, and team communication are normal duties relevant to the proposed specialist service.","Labor-cost bands can be anchored to approximately one to several scientific full-time equivalents before benefits, overhead, IT, legal, and laboratory costs."]},{"source_id":"S8","title":"JRC Nanobiotechnology Laboratory","publisher":"European Commission Joint Research Centre","url":"https://joint-research-centre.ec.europa.eu/laboratories-z/nanobiotechnology-laboratory_en","source_class":"OFFICIAL_ORGANIZATION_DATA","publication_date":"Not stated; page current at access","accessed_at":"2026-08-03","claims_supported":["JRC operates a multidisciplinary nanobiotechnology laboratory integrating physicochemical characterization with biological-interaction testing.","JRC offers external researchers governed access for proof-of-concept and technology-testing work.","A second public-sector adopter model exists, reinforcing both stakeholder pull and collision with established shared-service practice."]}],"problem_evidence":{"support":"STRONG","rationale":"The cross-domain problem is visible even though the candidate's exact local prevalence is unmeasured. MIRIBEL identifies inconsistent characterization and reporting as a significant bio-nano barrier; ISA-TAB-Nano documents incomplete and poorly integrated nanomaterial data; NIST documents preparation-dependent transformations and measurement-specific requirements; and NCL reports excessive endotoxin in nearly one-third of submitted formulations. These sources establish consequential interface, provenance, preparation, and contamination failures, but do not quantify handoff delay or duplicated effort at the unnamed participating facilities.","source_ids":["S2","S3","S4","S6"]},"stakeholder_evidence":{"support":"STRONG","rationale":"NCI is an identifiable funder and operator of a multidisciplinary standing characterization service created with FDA and NIST, with more than 500 nanomaterials tested. The European Commission JRC independently offers external access to an integrated nanobiotechnology facility. These are strong expressions of institutional need and authority, although no named facility has committed to this exact qualification-only pilot.","source_ids":["S1","S8"]},"prior_art":{"proximity":"ESTABLISHED_PRACTICE","closest_analogues":[{"name":"NCI Nanotechnology Characterization Laboratory and Assay Cascade","similarity":"A standing, multidisciplinary, publicly governed service repeatedly accepts external nanomaterials, coordinates tailored characterization, applies standardized protocols, and supports transition toward biological and regulatory evaluation.","remaining_difference":"The candidate is narrower: it would qualify an existing batch-and-record package for transfer between two facilities without taking over characterization or assay execution, and the receiving laboratory would retain independent acceptance.","source_ids":["S1","S5","S6"]},{"name":"MIRIBEL minimum-information framework","similarity":"Defines reusable material, biological, and protocol information needed to make bio-nano work interpretable and reproducible, closely matching the proposed semantic intake contract.","remaining_difference":"MIRIBEL is a reporting framework rather than an accountable, capacity-limited intermediary handling physical custody, exceptions, appeals, and repeated handoffs.","source_ids":["S2"]},{"name":"ISA-TAB-Nano","similarity":"Provides structured material, study, assay, protocol, endpoint, and ontology fields that could implement much of the proposed sample passport.","remaining_difference":"It is a data-exchange specification, not a staffed qualification service with independent acceptance, custody control, workload limits, and regeneration.","source_ids":["S3"]},{"name":"NIST nanoparticle sample-preparation and reporting protocols","similarity":"Prevalidate preparation and reporting procedures for nanoparticle dispersions intended for biological testing and explicitly address reproducibility.","remaining_difference":"They cover technical preparation methods rather than the bilateral trust, responsibility, custody, eligibility, and exception-routing layer.","source_ids":["S4"]},{"name":"JRC Nanobiotechnology Laboratory open-access service","similarity":"A multidisciplinary public facility offers external users integrated nanomaterial characterization and biological-interaction testing under governed access.","remaining_difference":"It is a centralized experimental infrastructure rather than a lightweight qualification broker between existing source and receiving facilities.","source_ids":["S8"]}],"distinctive_claim_remaining":"For a fixed, nonclinical material-and-assay envelope, a qualification-only intermediary using an ISA-TAB-Nano/MIRIBEL-informed passport can reduce median handoff elapsed time, clarification exchanges, and total cross-facility staff hours across repeated cases relative to ordinary bilateral coordination and a template-only comparator, without increasing false qualification, custody discrepancies, preparation deviations, unnecessary rerouting, downstream correction, or assay-queue burden. This is a local workflow-performance claim, not a new service-category claim.","confidence":"HIGH"},"implementation_evidence":{"support":"MODERATE","rationale":"The components are technically credible because NCI and JRC operate multidisciplinary services, structured reporting specifications exist, and NIST provides preparation protocols. A nonclinical pilot can remain within facility-director, sample-custodian, receiving-assay, and laboratory-safety authority if it does not alter samples without approval or certify safety. Important constraints remain: templates cannot be universal, empirical compatibility testing is necessary, regulated-product obligations remain with authorized actors, and confidentiality, intellectual-property, conflicts, custody, appeals, workload, and downstream capacity require local controls. No source demonstrates this exact qualification-only workflow or its effect size.","source_ids":["S1","S3","S4","S5","S6","S8"]},"scores":{"meaningful_impact":{"score":3,"rationale":"The underlying failures can impair reproducibility, interpretation, and safety, but the candidate provides no local volume, delay, or loss data and addresses only the handoff layer rather than assay capacity or scientific feasibility.","source_ids":["S2","S3","S4","S6"]},"stakeholder_pull":{"score":4,"rationale":"NCI and JRC visibly fund and operate closely related external-facing services, demonstrating strong institutional demand; a committed adopter for this exact pilot is still absent.","source_ids":["S1","S8"]},"incremental_advantage":{"score":2,"rationale":"The qualification-only, federated scope may be lighter than centralized characterization, but no evidence shows it outperforms ordinary coordination, MIRIBEL/ISA-TAB-Nano templates, or existing shared services.","source_ids":["S1","S2","S3","S8"]},"distinctiveness_plausibility":{"score":2,"rationale":"The service category, structured intake, standardized protocols, tailored review, and cross-disciplinary support are established. Only a narrow local workflow contrast remains.","source_ids":["S1","S2","S3","S4","S8"]},"technical_implementability":{"score":4,"rationale":"The proposal primarily composes established documentation, preparation, governance, and specialist-service practices using existing facilities; material-specific compatibility and contamination checks prevent a maximum score.","source_ids":["S1","S3","S4","S6","S8"]},"adoption_authority_feasibility":{"score":4,"rationale":"Facility directors, custodians, safety staff, and receiving-assay authorities can authorize a bounded nonclinical workflow while retaining existing acceptance powers. Clinical or regulated use would require additional authority and compliance review.","source_ids":["S1","S5","S8"]},"evidence_readiness":{"score":3,"rationale":"Observable outcomes and a six-case pilot are well bounded, but baseline data, partner commitment, precommitted thresholds, and independent adjudication arrangements are missing.","source_ids":["S2","S3","S4","S6"]},"safety_net_benefit":{"score":3,"rationale":"Structured provenance, contamination screening, exception routing, and unchanged acceptance criteria could reduce preventable errors, but a fast lane can also create false reassurance or gatekeeping unless independently audited.","source_ids":["S4","S5","S6"]},"scalability":{"score":3,"rationale":"Templates and structured records are reusable, but specialist judgment, material-specific validation, custody work, and receiving-assay capacity constrain turnover and generalization.","source_ids":["S1","S3","S4","S6","S8"]}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"10K_TO_50K","scope":"Design and run the pre-registered six-handoff nonclinical pilot using existing facilities, including matched ordinary-route and template-only exercises, staff-time capture, independent acceptance review, and analysis.","confidence":"MODERATE","assumptions":["No new analytical instrument or laboratory buildout.","Approximately 150-350 combined hours of specialist, scientist, technician, safety, data-custody, and evaluation effort.","Physical assays already required by the receiving facility are excluded because they occur in every comparator arm.","Salary anchor is approximately $103,650-$126,100 annually for relevant scientific labor before benefits and overhead."],"source_ids":["S7"]},"initial_deployment_startup":{"band_2026_usd":"50K_TO_250K","scope":"Configure the service for one facility pair: semantic contract, controlled templates, custody workflow, eligibility and appeal rules, basic case tracking, training, legal/IP review, and initial validation.","confidence":"MODERATE","assumptions":["Existing laboratory and institutional IT infrastructure are reused.","Roughly 0.5-1.5 loaded scientific or technical FTE-years plus limited software and governance support.","No validated clinical system, new LIMS, or major equipment purchase."],"source_ids":["S1","S3","S7"]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"Launch a durable multi-user service with a lead specialist, backup coverage, data/custody administration, quality review, dashboarding, training, incident response, and validation across several bounded material-assay envelopes.","confidence":"MODERATE","assumptions":["Two to four loaded FTE-equivalents across scientific, technical, data, quality, and administrative roles.","Existing analytical and biological facilities perform substantive tests.","Institutional overhead, benefits, modest IT integration, and validation consumables are included.","Expansion into clinical certification, major sample processing, or new laboratory construction is excluded."],"source_ids":["S1","S7","S8"]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Annual operation after launch: staffing, controlled-document maintenance, audits, training, relationship maintenance, appeals, template reauthorization, consumables, IT support, and independent quality oversight.","confidence":"MODERATE","assumptions":["Two to four loaded FTE-equivalents are maintained.","Case volume remains within existing laboratory and receiving-assay capacity.","Material-specific characterization and assay costs remain with the ordinary scientific projects rather than the handoff service.","The BLS wage anchor excludes benefits and institutional indirect costs, which are added within the band."],"source_ids":["S1","S7","S8"]}},"verified_pipeline_gates":{"externally_supported_problem":{"status":"YES","reason":"Independent research, standards guidance, and NCL operational data demonstrate incomplete reporting, preparation variability, contamination, and bio-nano reproducibility problems.","source_ids":["S2","S3","S4","S6"]},"externally_credible_adopter_or_authorizer":{"status":"YES","reason":"NCI/FDA/NIST and the European Commission JRC operate closely related multidisciplinary services; local facility directors and receiving-assay authorities are a credible authorization structure for a nonclinical probe.","source_ids":["S1","S8"]},"distinct_testable_incremental_claim":{"status":"YES","reason":"The qualification-only service can be tested against ordinary bilateral coordination and a template-only route on time, total labor, clarification, error, rerouting, custody, and downstream-load outcomes, although the broader practice is established.","source_ids":["S1","S2","S3"]},"bounded_next_evidence_step":{"status":"YES","reason":"A six-handoff nonclinical pilot with four routine and two deliberate exception cases, fixed comparators, independent acceptance, and precommitted falsifiers is bounded and feasible.","source_ids":["S3","S4","S6"]},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"For already authorized nonclinical samples, existing custodians, safety staff, and receiving-assay authorities can retain all substantive powers; stopping and reverting to ordinary review addresses uncertainty. This gate does not extend to clinical, animal, environmental-release, or regulatory certification uses.","source_ids":["S5","S6"]},"credible_cost_scope_and_range":{"status":"YES","reason":"The proposal can be scoped mainly by scientific and administrative FTEs using existing facilities, with BLS wages providing an external labor anchor. The bands remain planning estimates rather than vendor quotes.","source_ids":["S1","S7","S8"]}},"next_evidence_step":"At one named source/assay facility pair, pre-register six already authorized nonclinical handoffs: four routine cases inside one fixed material-assay envelope and two seeded exception cases. Randomize routine cases between (A) ordinary bilateral coordination and (B) the staffed qualification service; also run a blinded document-only review using (C) the same passport/template without the intermediary. Keep sample, assay-entry, safety, custody, and receiving staff rules unchanged. Measure end-to-end elapsed time, total labor by actor, clarification exchanges, duplicated characterization, acceptance and reroute accuracy, custody discrepancies, preparation deviations, sample loss, post-acceptance corrections, appeals, closeout effort, specialist recovery time, and receiving-queue change. Continue only if the service beats both comparators beyond baseline variation on time and total labor, all two deliberate exceptions are rerouted, and no safety, custody, false-qualification, downstream-correction, or queue metric worsens. Falsify the claim if template-only performance is equivalent, specialist effort scales approximately one-for-one with cases, any exception is falsely qualified, gains depend on relaxed criteria or easy-case selection, or downstream burden merely shifts.","blocking_evidence":["No site-specific evidence quantifies how often translation, trust, evidence reconstruction, or custody—rather than assay capacity or unresolved science—is the binding constraint.","No named pair of facilities has expressed commitment to authorize or fund this exact qualification-only service.","No live comparison establishes advantage over ordinary bilateral coordination, MIRIBEL/ISA-TAB-Nano templates alone, or an existing centralized characterization service.","Cost bands are resource-equivalent planning estimates, not local salary, indirect-cost, software, consumables, or vendor quotations.","No local confidentiality, intellectual-property, data-governance, sample-custody, conflict-of-interest, or labor-relations review has been completed.","World novelty, patentability, freedom to operate, market size, and realized impact remain unmeasured."],"research_disposition":"KNOWN_PRACTICE_DIFFUSION","world_novelty_boundary":"World novelty was not measured. Bounded search found established public-sector nano-bio characterization services, minimum-information frameworks, nanomaterial data specifications, and preparation protocols that cover most proposed components. The only remaining contrast is a narrower federated, qualification-only implementation and its local comparative performance; this does not establish patentability, freedom to operate, market novelty, or novelty worldwide.","arm":"COMPLETE_PROPOSAL_PORTFOLIO","candidate_version":0,"controller_recommendation":{"action":"STOP_DIFFUSION","repairable":false,"material_progress_observed":true,"progress_targets":["Treat the standing nano-bio service model as established practice and frame further work as local adoption or diffusion, not invention validation.","Before adoption, name a facility pair and document baseline handoff volume, delays, labor, custody errors, preparation deviations, and downstream capacity.","Reuse or explicitly map MIRIBEL, ISA-TAB-Nano, NIST protocols, and applicable FDA requirements instead of creating an ungrounded new passport.","Run the bounded three-comparator pilot only to establish local incremental value, with independent acceptance and exception-detection falsifiers.","Obtain local cost quotations and complete confidentiality, IP, custody, conflict, workload, appeal, and safety-authority reviews."],"reason":"The problem and adopter class are externally supported, but the central intervention substantially matches established NCI and JRC shared-service practice and composes existing reporting and preparation standards. The remaining qualification-only contrast is suitable for local diffusion testing, not continuation as a distinct innovation opportunity."},"proposal_index":4}